Herschorn S, Nazir J, Ramos B, Hakimi Z. Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. CUAJ [Internet]. 2017 Apr. 11 [cited 2024 May 1];11(3-4):123-30. Available from: https://cuaj.ca/index.php/journal/article/view/4114